Diseases information. Disorders. Treatment.

Despite the large number of clinical studies, there are important unanswered issues concerning the management of patients with ischemic cerebrovascular events. In the acute management of stroke, there are many ongoing clinical trials with antithrombotic drugs, as well as neuroprotective agents, which are being tested with time windows of 90 minutes to 48 hours. For the long-term protection from stroke, clinical trials have yielded alternatives: antiplatelet agents and warfarin. The choice of the best therapy depends upon recognizing the clinical syndrome, determining the infarct subtype, and evaluating risk factors. For certain high-risk conditions such as nonvalvular atrial fibrillation, prosthetic valves, acute myocardial infarction, and cardioembolic stroke, warfarin is probably indicated. The dose, duration, need for combination therapies, and role of warfarin in non-cardioembolic stroke are remaining questions. Clearly, more work needs to be done in the prevention and treatment of ischemic stroke to achieve our goals of reducing the public health burden of stroke.

In the acute setting, thrombolysis with TPA has been approved by the FDA for the treatment of ischemic stroke where the therapy can be instituted within 3 hours of symptoms. The NIH TPA trials demonstrated a consistent and persuasive improvement in 3-month outcome based on the NIH Stroke Severity Scale, Glasgow Outcome Score, Barthel Index of Activities of Daily Living and the Rankin Score (Global Test OR=l.7, p=0.008). The TPA was given at a dose of 0.9 mg per Kg for a maximum of 90 mg with 10% as a bolus and the remainder through a 1-hour IV infusion. There was an elevated risk of intracerebral hemorrhage or hemorrhagic infarction (symptomatic intracranial hemorrhage risk of 6% to 7%). There were numerous exclusion criteria including no evidence of any recent bleeding or chance of bleeding diathesis or uncontrolled hypertension. We must choose our patients accordingly when we consider the use of TPA.
Cialis professional
Data from the International Stroke Trial and the Chinese Aspirin Stroke Trial have indicated that the use of aspirin acutely among patients treated within 48 hours will reduce stroke recurrence risks and mortality. The use of heparin is still controversial. Subcutaneous heparin at 12500 BID was found to increase the risk of hemorrhage, while 5000 BID seemed safe and offered some protection from early death, stroke recurrence, and PE. Recent results from the TOAST trial which compared low molecular weight heparinoid to placebo among patients with ischemic stroke treated within 24 hours were not significant except for the atherosclerotic subgroup. Further studies are being planned.
Canadian pharmacy levitra
Numerous acute stroke trials are being conducted or have recently been completed with various neuroprotective agents such as Lubeluzole, Glycine antagonists and NMDA antagonists. The future seems promising that another agent will prove useful in reducing the mortality and morbidity from ischemic stroke.

Warfarin is an oral anticoagulant which has been demonstrated to be effective in the prevention of cardioembolic stroke. Recent randomized clinical trials have evaluated the relative merits of warfarin or aspirin in patients with asymptomatic nonvalvular atrial fibrillation. Warfarin is beneficial among patients with prosthetic valves and after acute myocardial infarction to reduce the risk of thromboembolic stroke. Those with mechanical valves are usually treated with long-term oral anticoagulants, while those with bioprosthetic valves may be treated with antiplatelet agents. The combination of low-dose aspirin with warfarin was found to be more effective than warfarin alone in reducing mortality and major systemic embolism among patients with prosthetic valves plus atrial fibrillation or a history of thromboembolism. In the Warfarin Reinfarction Study, warfarin was superior to placebo in reducing the likelihood of recurrent MI, mortality, and the incidence of cerebrovascular events among patients under age 75 with acute myocardial infarction. Findings on echocardiogram such as anterior wall akinesis and left ventricular thrombus may help determine who is at increased risk of stroke and select such patients for a 3-6 month course of oral anticoagulants. Combination therapy of warfarin and aspirin is also being evaluated after acute myocardial infarction.
Canadian health care mall
For patients who have already become symptomatic with transient ischemic attacks or ischemic stroke and have a cardiac source of embolism, the European Atrial Fibrillation Trial convincingly demonstrated that anticoagulation therapy reduced the risk of recurrent stroke in patients with atrial fibrillation and TIA or minor stroke from 12% to 4% compared to placebo. The risk reduction of 67% was similar to that found in the other atrial fibrillation trials among persons with no prior neurological events. Oral anticoagulants were more effective than aspirin, and aspirin was better than placebo, but the latter effect was not significant. This clinical trial, in conjunction with the other warfarin studies, provides support that warfarin is the therapy of choice in patients with a cardiac source and a TIA or minor stroke, providing there is no contraindication to its use.
Hgh online pharmacy
At present, there is considerable debate concerning the use of warfarin after noncardioembolic stroke or TIA and no recent clinical trial evidence to support its use. Most of the early trials were done during the pre-computed tomography, pre-echocardiography era and found no benefit for warfarin. However, many of the studies had an unacceptably small sample size, no clearly defined mechanism of stroke, a higher rate of recurrent stroke than is common at the present time, and far higher rates of anticoagulant complications than those which occur currently. Recently, the SPIRIT (Stroke Prevention in Reversible Ischemia Trial) had to be halted because of the hemorrhagic side effects of an INR of 3-4.5 for patients with nondisabling, noncardioembolic infarction. The debate should be settled by the ongoing Warfarin Aspirin Recurrent Stroke Study which was designed to compare the efficacy of warfarin to aspirin for the prevention of recurrent Stroke or death after noncardioembolic stroke. This randomized, double-blind clinical trial has begun recruiting nearly 2000 patients with non-cardioembolic, non-operable atherosclerotic stroke over age 18 among 50 centers. Patients are followed for 2 years to detect the primary endpoints of recurrent stroke or death and other cardiovascular secondary events. All patients are treated as if they are taking warfarin with monthly prothrombin times. Sham prothrombin times are generated for the aspirin group based on a computer model of actual variations in prothrombin time among patients treated with warfarin. Some important questions regarding the role of warfarin for prevention of recurrent stroke will be answered at the conclusion of this trial in 2006.

Ticlopidine
Viagra professional
The other antiplatelet agent that has proven efficacy in stroke prevention is ticlopidine. In the Canadian American Ticlopidine Study, ticlopidine was compared to placebo after a completed non-cardioembolic stroke among 1053 patients. Ticlopidine resulted in a 23% risk reduction in an intention-to-treat analysis and a 30% reduction in the efficacy analysis. The risk reduction for nonfatal or fatal recurrent stroke was 33%. In the Ticlopidine Aspirin Stroke Study, ticlopidine was compared to aspirin (1300 mg/day) among 3069 patients with TIA or minor stroke. Overall, there was a 12% reduction in stroke or death at 3-years, but a 47% risk reduction in fatal or non-fatal stroke was observed during the first year for those treated with ticlopidine compared to aspirin. Benefits were found both among men and women and the effect was observed in the subgroup with minor stroke.

Dipyridamole

Trials using other antiplatelet agents, such as sulfinpyrazone and suloctidil, have not been as effective as aspirin or have not demonstrated any added benefit to aspirin alone. Dipyridamole was not thought to have any added benefit to aspirin based on the French AICLA trial, however results from the European Stroke Prevention Stroke Study II have indicated that 200 mg BID of modified-release Dipyridamole was more effective than Aspirin (25 mg BID) in the prevention of stroke, myocardial infarction and vascular death after TIA or minor stroke. In this trial 6602 patients were randomized in a factorial design, 76% with stroke and 24% with TIAs. Primary endpoints were stroke, death, and stroke or death together. Patients were followed for 2 years. The relative risk reduction of stroke was 18% for aspirin, 16% for dipyridamole, and 37% for the combination of the two. The relative risk reduction of stroke or death was 13% for aspirin, 15% for dipyridamole, and 24% for the combination of the two. Factorial analysis also demonstrated a highly significant effect of ASA and dipyridamole for preventing TIA. Headache was the most common adverse event and occurred more frequently in the dipyridamole group. Bleeding and GI hemorrhage was more common in patients taking ASA compared to placebo or dipyridamole. The combined long-acting formulation is not yet available or approved in the U.S.
Levitra professional
Clopidogrel

Clopidogrel, a thienopyridine derivative similar to ticlopidine, is a new antiplatelet agent which is an inhibitor of platelet aggregation induced by adenosine diphosphate. This agent at a dose of 75 mg BID was recently compared to aspirin (325 mg per day) in reducing the risk of ischemic stroke, myocardial infarction, or vascular death among patients with atherosclerotic vascular disease. Nearly 20,000 patients with stroke, MI, or peripheral vascular disease were recruited over 3 years with a mean follow-up of 1.9 years. Patients treated with clopidogrel had a 5.32% risk of stroke, MI, or vascular death compared to 5.83% with ASA (p=.043). Among the stroke subgroup, there was a nonsignificant reduction from 7.71% to 7.15% in outcome events, however the number of non-fatal strokes were reduced from 322 to 298 with clopidogrel. The most significant effects were observed for the subgroup with PAD. Among patients with PAD or stroke with a prior history of MI, the event rate reduced from 10.74% to 8.35% with clopidogrel (relative risk reduction of 22.7%). The medicine was safe and was not associated with an increased risk of neutropenia. The drug is now FDA approved.

Antithrombotic agents are ultimately aimed at interfering with the process of thrombosis or formation of intravascular clot which involves platelets and fibrin. Antiplatelet agents deter the adherence of platelets to the wall of an injured vessel or to one another. This is an early step in the generation of a thrombus. Anticoagulants prevent the formation and propagation of fibrin which is the essential building block of a thrombus. For cerebral ischemia, a variety of antithrombotic agents have been proven to be of value in the prevention of ischemic stroke after transient ischemic attack, completed infarction, or when certain high-risk conditions are detected such as nonvalvular atrial fibrillation, valvular heart disease, or after acute myocardial infarction. These antithrombotic agents include antiplatelet drugs (aspirin, ticlopidine, dipyridamole, and clopidogrel) and anticoagulants (warfarin). New antiplatelet agents are being tested in a variety of circumstances among patients with cerebrovascular disorders. Canadian viagra online pharmacy.

Aspirin

Numerous clinical trials have been done comparing aspirin with placebo for the prevention of stroke and death after TIA or minor stroke.The Antiplatelet Trialist Collaboration Group have used meta analyses to combine the results of these various antiplatelet studies in which ASA was the most widely used agent. In their most recent analyses of 17 trials among persons with a past history of stroke or TIA, they reported an odds reduction of 22% for non-fatal stroke, non-fatal MI or vascular death with a 2-year risk of 18% for those treated with antiplatelets and 22% for controls. Few of the individual aspirin studies were directed at the efficacy of aspirin in preventing recurrent stroke after an established stroke. In the meta-analyses among those with a completed stroke, the odds reduction was 16% for non-fatal stroke, non-fatal MI or vascular death. Individual aspirin studies have sometimes failed to find a beneficial effect for women. However, in the meta-analyses similar reductions were found for women and men, young and old, hypertensives and normotensives and diabetics and non-diabetics.
Canadian generic viagra
The issue of the dose of aspirin needed to prevent stroke is still controversial. Recommendations range from a low of 30 mg per day to a high of 1300 mg per day. The data for the efficacy of stroke prevention for lower doses is available only from trials involving patients with TIA and minor stroke. Gastrointestinal hemorrhage and other aspirin-related side effects are clearly reduced with the lower doses. The Antiplatelet Trialist’s Collaboration Report cited three trials using doses of 300-325 daily and compared the outcome for major vascular events, including stroke, to the 15 trials using 900-1500 daily. Cheap generic lipitor. The authors concluded “…the studies of 300-325 mg/day appeared to have yielded results that were at least as good as those yielded by 900-1500 mg/day.” However, a review of stroke trials found that the risk reductions were not as great with the low dose aspirin programs compared to the higher dose programs. They stated that this “raised the possibility that 325 mg/day or less of aspirin may not be equally effective as 975 mg/day or more.” The data from aspirin trials suggest that a dose of aspirin as low as 325 mg is better tolerated and might prove as effective as the higher doses of 1000-1300 mg. In 2006, the US Food and Drug Administration revised their recommendations to endorse 50-325 mg of ASA per day as the standard dose to prevent stroke in TIA and stroke survivors.

Cialis professional
Specific Treatments for Patients with Tia or Minor Stroke
Depending on the mechanism of the cerebral ischemic event, there are now options from which to chose for the prevention of first or recurrent stroke. Newer treatments such as thrombolysis and neuroprotection may prove beneficial in the acute setting, while other therapies are aimed at reducing the stroke recurrence risk. One early decision which must be addressed among patients presenting with TIAs or minor strokes is whether to chose surgery versus medical therapies for stroke prevention.

Carotid Endarterectomy
Surgical clinical trials have documented the benefit of carotid endarterectomy to reduce the risk of ischemic stroke in some symptomatic persons. In the North American Symptomatic Carotid Endarterectomy Trial (NASCET) among persons with TIA or minor stroke and an ipsilateral carotid stenosis of 70% or more, the 2-year risk of ipsilateral stroke was 9% in the surgical group and 26% in the medical group (ASA 1300 mg/day). The VA Cooperative Study showed that among those with greater than 50% carotid stenosis, the risks of stroke after a mean follow-up of 11.9 months were 7.7% in the surgical group and 19.4% in the non-surgical group. The European Carotid Surgery Trial (ECST) demonstrated similar findings as in the latter two studies for high-grade symptomatic carotid stenosis, but there was no significant benefit of surgery for those with 0-29% stenosis. Recent NASCET data has extended the benefits of carotid endarterectomy to persons with symptomatic carotid stenosis of greater than 50%. This degree of stenosis is based on the NASCET angiographically-based measurement and is equivalent to approximately 75% stenosis by ECST criteria and greater than 60-80% stenosis by carotid Duplex Doppler criteria.
The consensus is clear that for patients with a TIA or minor stroke and ipsilateral carotid stenosis more than 50-60%, then carotid endarterectomy is the best option for prevention of a recurrent event. For those with <50-60% stenosis, endarterectomy offers little benefit compared to medical therapy.